Lv31
210 积分 2026-01-13 加入
Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial
42分钟前
已完结
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
53分钟前
已完结
Prevalence of Metabolic Syndrome among Apparently Healthy Adult Population in Pakistan: A Systematic Review and Meta-Analysis
1个月前
已关闭
Lipid-Lowering Therapy in the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia
1个月前
已完结
LDL-C–Related Cardiovascular Burden in China 2010 to 2030
1个月前
已完结
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
2个月前
已完结
Genetics: HMGCR and PCSK9 variants and cardiovascular risk
2个月前
已完结
Experimentally Validated SLC6A19 Loss-of-Function Variants Improve Kidney Function and Reduce Progression to Kidney Failure
3个月前
已关闭
Machine learning assessment of pathologic response in lung cancer resections after neoadjuvant therapy - IASLC MPR Project
4个月前
已关闭
皖公网安备34019202002308
